Clinical Report: A-DREAM/Alliance A032101 Study Findings
Overview
The A-DREAM/Alliance A032101 study reveals that 41% of patients who responded favorably to testosterone suppression combined with an androgen receptor pathway inhibitor remained treatment-free with testosterone recovery at 18 months post-treatment interruption.
Background
The management of metastatic hormone-sensitive prostate cancer (mHSPC) is evolving, particularly with the introduction of androgen receptor pathway inhibitors (ARPI) alongside androgen deprivation therapy (ADT). Understanding the long-term effects of treatment interruption in patients responding well to these therapies is crucial.
Data Highlights
No numerical data available in the source material.
Key Findings
- 41% of favorable responders to testosterone suppression plus ARPI remained treatment-free at 18 months.
- Testosterone recovery was observed in these patients after treatment interruption.
Clinical Implications
The findings suggest that treatment interruption may be a viable strategy for select patients with mHSPC who respond favorably to initial therapy. Clinicians should consider monitoring testosterone levels and patient responses closely when contemplating treatment interruption.
Conclusion
The A-DREAM/Alliance A032101 study provides insights into treatment-free intervals in mHSPC management.
Related Resources & Content
- Choudhury A, ASCO 2026 — A phase 2 trial of androgen deprivation therapy interruption in patients responding exceptionally to androgen receptor pathway inhibitor in metastatic hormone-sensitive prostate cancer (A-DREAM / Alliance A032101).
- The ASCO Post — ASCO Honors 2022 Special Awards Recipients
- the asco post — ASCO Thanks Richard L. Schilsky, MD, FACP, FSCT, FASCO, for His Vision and Leadership of TAPUR
- the asco post — ASCO Thanks Richard L. Schilsky, MD, FACP, FSCT, FASCO, for His Vision and Leadership of TAPUR
- roswell park comprehensive cancer center — ASCO 2025 Highlights: Menin Inhibitor for Acute Myeloid Leukemia; Organ Transplant and Checkpoint Inhibitors
- 2026 AUA/SUO Advanced Prostate Cancer Guideline: Key updates and clinical FAQs
- https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-EANM-ESTRO-ESUR-ISUP-SIOG-Guidelines-on-Prostate-Cancer-2026_2026-03-14-104356_ixav.pdf
- Real-world trends in the evolving use of first-line therapy in metastatic castration-sensitive prostate cancer patients (mCSPC) in the United States. | Journal of Clinical Oncology
- Predictors of treatment (tx) duration in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) treated with enzalutamide (ENZA): A post hoc analysis of ARCHES. | Journal of Clinical Oncology
- A phase 2 trial of androgen deprivation therapy interruption in patients responding exceptionally to androgen receptor pathway inhibitor in metastatic hormone-sensitive prostate cancer (A-DREAM / Alliance A032101). | Journal of Clinical Oncology
- ASCO 2026: A Phase 2 Trial of ADT Interruption in Patients Responding Exceptionally to Androgen Receptor Pathway Inhibitor in mHSPC (A-DREAM / Alliance A032101)
- Treatment interruption guided by on-treatment prostate-specific membrane antigen (PSMA) PET/CT imaging in metastatic hormone-sensitive prostate cancer (mHSPC). | Journal of Clinical Oncology
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
